How Many Pneumocystis Jirovecii Pneumonia Cases, in CHUS Hospital from 2008 to 2018, Resulted of Omission of Antibioprophylaxis in Patients With Rheumatic Diseases?

被引：0
|
作者：
Page, Charles [1 ]
Brum-Fernandes, Artur [1 ]
机构：
[1] Univ Sherbrooke, Sherbrooke, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
40
引用
收藏
页码：1134 / 1134
页数：1
相关论文
共 18 条
  • [1] Risk Factors of Pneumocystis Jirovecii Pneumonia in Patients with Rheumatic Diseases
    Ekren, P. Korkmaz
    Nesil, I.
    Zihni, F. Yargucu
    Guruz, A.
    Toz, S.
    Turgay, N.
    Sayiner, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [2] Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases
    van den Hombergh, Wieneke
    van Ede, Annelies
    Fransen, J.
    Lamers-Karnebeek, Femke B. G.
    Kuipers, Saskia
    Janssen, Matthijs
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S579 - S579
  • [3] Reduction of Pneumocystis jirovecii pneumonia and bloodstream infections by trimethoprim-sulfamethoxazole prophylaxis in patients with rheumatic diseases
    Honda, N.
    Tagashira, Y.
    Kawai, S.
    Kobayashi, T.
    Yamamoto, M.
    Shimada, K.
    Yokogawa, N.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 (05) : 365 - 371
  • [4] Pneumocystis jirovecii pneumonia in patients treated with rituximab for systemic diseases: Report of 11 cases and review of the literature
    Alexandre, K.
    Ingen-Housz-Oro, S.
    Versini, M.
    Sailler, L.
    Benhamou, Y.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018, 50 : E23 - E24
  • [5] Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
    C. A. Pereda
    M. B. Nishishinya-Aquino
    N. Brito-García
    P. Díaz del Campo Fontecha
    I. Rua-Figueroa
    Rheumatology International, 2021, 41 : 1419 - 1427
  • [6] Risk-Benefit Analysis of Primary Prophylaxis Against Pneumocystis Jirovecii Pneumonia in Patients With Rheumatic Diseases Receiving Rituximab
    Park, Jun Won
    Curtis, Jeffrey R.
    Choi, Se Rim
    Kim, Min Jung
    Ha, You-Jung
    Kang, Eun Ha
    Lee, Yun Jong
    Lee, Eun Bong
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (11) : 2036 - 2044
  • [7] Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
    Pereda, C. A.
    Nishishinya-Aquino, M. B.
    Brito-Garcia, N.
    Diaz del Campo Fontecha, P.
    Rua-Figueroa, I.
    RHEUMATOLOGY INTERNATIONAL, 2021, 41 (08) : 1419 - 1427
  • [8] Clinical Characteristics and Outcomes of Pneumocystis jirovecii Pneumonia in Cancer Patients From a Tertiary Care Hospital
    Shehbaz, Muhammad
    Aslam, Seemal
    Arslan, Muhammad
    Nizamuddin, Summiya
    Ali, Sajid
    Abbas, Salma
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
  • [9] Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs
    Schmajuk, Gabriela
    Jafri, Kashif
    Evans, Michael
    Shiboski, Stephen
    Gianfrancesco, Milena
    Izadi, Zara
    Patterson, Sarah L.
    Aggarwal, Ishita
    Sarkar, Urmimala
    Dudley, R. Adams
    Yazdany, Jinoos
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 48 (06) : 1087 - 1092
  • [10] Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study
    Ohmura, Shin-ichiro
    Naniwa, Taio
    Tamechika, Shin-ya
    Miyamoto, Toshiaki
    Shichi, Daisuke
    Kazawa, Nobukata
    Iwagaitsu, Shiho
    Maeda, Shinji
    Wada, Jun-ichi
    Niimi, Akio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2019, 25 (04) : 253 - 261
12